Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07493993 für Ösophagus-Plattenepithelkarzinom ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche
Medizinische Universität TianjinClinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Phase 2 26
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07493993 untersucht Behandlung im Zusammenhang mit Ösophagus-Plattenepithelkarzinom. Diese interventionsstudie der Phase 2 hat den Status noch nicht rekrutierend. Der Start ist für 1. Juni 2026 geplant, bis 26 Teilnehmer aufgenommen werden. Durchgeführt von Medizinische Universität Tianjin wird der Abschluss für 31. Dezember 2030 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. März 2026 aktualisiert.
Kurzbeschreibung
Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.
Ausführliche Beschreibung
This clinical study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.This study consists of three phases: screening, treatment, and follow-up.Efficacy evaluation and safety monitoring should be performed th...Mehr anzeigen
Offizieller Titel
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Erkrankungen
Ösophagus-PlattenepithelkarzinomWeitere Studien-IDs
- E20260292
NCT-Nummer
Studienbeginn (tatsächlich)
2026-06-01
Zuletzt aktualisiert
2026-03-27
Studienende (vorauss.)
2030-12-31
Geplante Rekrutierung
26
Studientyp
Interventionsstudie
PHASE
Phase 2
Status
Noch nicht rekrutierend
Stichwörter
Iparomlimab and Tuvonralimab Injection
Nab-Paclitaxel
neoadjuvant therapy
ESCC
Nab-Paclitaxel
neoadjuvant therapy
ESCC
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Experimentelllparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel | lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel Iparomlimab and Tuvonralimab Injection: 5 mg/kg, q3w; Nab-Paclitaxel: 125 mg/m² on d1 and d8, q3w; Neoadjuvant therapy is administered for 4 cycles. The appropriate surgical timing will be determined by the physician based on the patient's condition, and surgery is scheduled for 4-6 weeks after the completion of neoadjuvant therapy. |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Pathologic complete response rate (pCR) | refers to the absence of viable tumor cells in both the primary tumor bed and the regional lymph nodes in the surgically resected specimens. | up to 6 month |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Major Pathologic Response rate (MPR) | up to 12 month | |
R0 Resection rate | up to 12 month | |
Event-Free Survival (EFS) | up to 12 month | |
Disease-Free Survival (DFS) | up to 12 month | |
Overall survival | Os was defined as the time from the first dose of study drug to death due to anycause. | up to 36 month |
Adverse Events | An AE was defined as any untoward medical occurrence in a pharmaceutical productwhich does not necessarily have to have a causal relationship with this treatment. | up to 36 month |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
- Voluntarily understand and sign the informed consent form for this study.
- Age ≥ 18 years, male or female.
- Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition).
- ECOG performance status of 0-2.
- No prior treatment for esophageal squamous cell carcinoma.
- Life expectancy ≥ 3 months.
- Adequate function of major organs within 7 days before the first treatment (use of any blood components or cell growth factors within 14 days before enrollment is not permitted):Hemoglobin ≥ 90 g/L; White blood cell count ≥ 3.5 × 10^9/L; Absolute neutrophil count ≥ 1.5 × 10^9/L; Platelets ≥ 80 × 10^9/L; AST and ALT ≤ 2.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL/min); Left ventricular ejection fraction (LVEF) ≥ 50%.
- Fertile patients must agree to use reliable contraceptive methods with their partner during the trial and for at least 180 days after the last dose.
- Inability to comply with the study protocol or study procedures.
- Presence of supraclavicular lymph node metastasis.
- Obvious tumor invasion of organs adjacent to the esophageal lesion.
- Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment.
- Allergy or known hypersensitivity to the study drugs or their excipients.
- Anticipated need for systemic corticosteroids or other immunosuppressive therapy during the study treatment period.
- Active autoimmune disease requiring systemic treatment, or a history of autoimmune disease.
- Positive HIV test; positive hepatitis B surface antigen with HBV-DNA > upper limit of normal; active hepatitis C virus (HCV) infection.
- History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months before the first study drug administration; known severe varices on endoscopy within 3 months before the first study drug administration.
- Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia that might interfere with the assessment and management of immune-related pulmonary toxicity.
- Evidence of a significant bleeding tendency or other major coagulation disorders.
- Severe cardiovascular or cerebrovascular disease.
- Other malignancies within 5 years before enrollment, except for radically resected basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.
- History of allogeneic bone marrow transplantation or organ transplantation.
- Patients considered by the investigator to be unsuitable for participation in this study.
Medizinische Universität Tianjin378 aktive klinische Studien zum ErkundenZentrale Studienkontakte
Kontakt: Zhansheng Jiang, Doctor, 13512035574, [email protected]
Kontakt: Chang Liu
1 Studienstandorte in 1 Ländern
Tianjin Municipality
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, 300000, China
Zhansheng Jiang, Kontakt, 13512035574, [email protected]